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Available online 3 February 2016Background: Levosimendan is an inodilator developed for treatment of acute heart failure and other cardiac con-
ditions where the use of an inodilator is considered appropriate. Levosimendan has been studied in different
therapeutic settings including acutely decompensated chronic heart failure, advanced heart failure, right ventric-
ular failure, cardiogenic shock, septic shock, and cardiac and non-cardiac surgery. This variety of data has been
re-analysed in 25 meta-analyses from 15 different international research groups, based on different rationales
to select the studies included.
Methods:We here review all previously published meta-analyses on levosimendan to determine any common
denominators for its effects on patient mortality. In addition, we also perform a comparative meta-analysis of
the six phase II and III randomized double-blind trials which were taken into consideration by the regulatory
authorities for the purpose of introducing levosimendan into the market.
Results: Irrespective of clinical setting or comparator, all meta-analyses consistently show beneﬁts for
levosimendan, with lower relative risk (or odds ratio) for patient mortality. In 3/25 of the meta-analyses these
beneﬁcial trends did not reach statistical signiﬁcance, while in 22/25 signiﬁcance was reached. The relative risk
is consistent overall, and very similar to that obtained in our own meta-analysis that considered only the
‘regulatory’ studies.
Conclusion: The existing meta-analyses, now based on a population of over 6000 patients, provide the general
message of signiﬁcant beneﬁts for levosimendan in terms of patient mortality. The weight of evidence is
now clearly in favour of usefulness/efﬁcacy of levosimendan, with data from multiple randomized trials and
meta-analyses., P.O.
. Polle
land© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Inodilator1. Introduction
Levosimendan is a calcium sensitizer and ATP-dependent potassium
channel opener [1] that was developed as an inodilating drug for use in
the treatment of acute heart failure (AHF) or other cardiac situations
where an inodilator is considered appropriate [2].
Over the last two decades, many studies have been conducted to de-
termine the effects of levosimendan in different therapeutic settings [2],
such as acutely decompensated chronic heart failure, advanced heart
failure, right ventricular failure, and cardiogenic shock, and also in septic
shock, and cardiac and non-cardiac surgery. In a search of PubMed
on September 2015, 184 papers were found that describe the results
of clinical trials of levosimendan in cardiology, cardiac surgery, and
cardiac-anaesthesiology, and in the intensive care setting. In the latest
20 years levosimendan has been compared to several other drugs,Box 65, Espoo, Finland.
sello).
Ltd. This is an open access articlsuch as dobutamine, milrinone, and enoximone, as well as alone or as
an addition to best standard of care. The comparison to placebo has
been obscured by the fact that studies allowed for other inotropes or va-
soactive drugs to be used either as best standard of care or as rescue
drugs in both arms. Among these studies, six are the phase II and III
randomized double-blind trials that were included in the regulatory
proceedings for the registration of i.v. levosimendan in Europe and
Latin America.
To date, this plethora of information has been re-analysed in 25
meta-analyses by 16 different international research groups. These
analyses have been also different in terms of clinical settings in which
levosimendan was considered, selection of comparators, endpoints
measured, and statistical tools used. Each research group also used
different rationales to select the studies to be included in their
meta-analyses, with some being more strict, and others being more
comprehensive.
As the number of meta-analyses in the medical literature is overall
growing [3], we decided to review all of the published meta-analysese under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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light on the effects of this drug.
2. Methods
Two of the authors (PP, MK) independently searched PubMed for
b‘meta-analysis’ AND ‘levosimendan’N between Nov. 1995 and Nov.
2015, and obtained 37 hits. From this list, 12 reports were considered ir-
relevant because they were either pooled analyses, letters, editorials,
comments, or reviews. The remaining 25 meta-analyses [4–28] were
analysed systematically for their clinical setting, number of studied,
endpoints, statistical tools, results, and ﬁnally, statistical signiﬁcance of
the conclusions. The identity and geographical locations of the research
groups were also collected, to deﬁne multiple meta-analyses from the
same groups.
We also performed an additional comparative meta-analysis on
the effect of levosimendan on patient mortality through the selection
of only the six phase II and III randomized double-blind trials that
were ﬁled by the originator and taken into consideration by the reg-
ulatory authorities for the purpose of introducing levosimendan into
the market [29–34]. The rationale of this study selection is based on
the fact that only such studies are usually considered as ﬁtting the
approved settings for the use of a drug. The data on outcome extracted
from those papers were analysed with RevMan 5.2 (freeware available
from The Cochrane Collaboration) [35]. The pooled statistics were
calculated using Cochran–Mantel–Haenszel tests, controlling for each
study.
3. Results
The 25meta-analyses considered in this review are listed in chrono-
logical order in Table 1. For each of these studies, this includes year of
publication, name of the ﬁrst author, country of origin of the research
group (in a few cases there were multiple countries), clinical settings,
number of studies included, comparator(s) used in the studies, main
end-point, result of themeta-analysis on that main endpoint expressed
as relative risk if not otherwise speciﬁed (also odds ratio, risk ratio, risk
difference, and z-test valuewere in fact used), and ﬁnally, statistical sig-
niﬁcance of the main result.
The authorship of these 25 meta-analyses was divided among 16
research groups from eight countries as: eight analyses from Italy
(from one research group) [6,7,9,12,18,20,21,25,27], ﬁve from China
(from ﬁve different research groups) [14,16,22,24,28], three from the
U.K. (from two research groups) [4,5,11], and one each from Brazil [8],
Australia [10], Spain [13], U.S.A [15], and The Netherlands [19]. Finally,
three meta-analyses were published by international research groups
with authorship scattered across two or more countries [17,23,26].
In further detail, ﬁve of these 25meta-analyses considered all of the
clinical trials on levosimendan [7,12,14,19,27], ﬁve focused on the ef-
fects of levosimendan in AHF [4,5,8,10,24], four on the effects of repeti-
tive infusions of levosimendan in advanced chronic heart failure (AdHF)
[17,18,22,26], ten on the peri-operative uses of levosimendan in cardiac
surgery [6,9,11,13,15,16,20,21,23,28] (two of them describing mainly
the effects of the drug on the kidney [16,20]), and ﬁnally one on sepsis
and septic shock [25].
Finally, we collected the data from the six phase II and III random-
ized double-blind trials on levosimendsan [29–34] that were ﬁled by
the originator and taken into consideration by the regulatory authorities
for the purpose of introducing levosimendan into the market. These
trials included the dose-ﬁnding study by Slawsky et al. [29], the dose-
escalation and withdrawal study by Nieminen et al. [30], the LIDO
study by Follath et al. (vs. dobutamine) [31], the RUSSLAN study by
Moiseyev et al. (vs. placebo) [32], the SURVIVE study by Mebazaa
et al. (vs. dobutamine) [33], and the REVIVE (I and II) study by Packer
et al. (vs. placebo on top of standard of care) [34].When we performed a comparative meta-analysis on the effects of
levosimendan on patient mortality with the selection of only these six
studies (Fig. 1), we obtained a risk reduction of 0.82 (95% CI = 0.67;
1.01) which is in linewith all of themeta-analyses included in the pres-
ent review, although this was only showing a strong trend for a differ-
ence (p = 0.054).
3.1. Meta-analyses for levosimendan in all settings
Five meta-analyses considered all of the clinical trials on
levosimendan in all settings [7,12,14,19,27]. One of them was per-
formed by a research group in the Netherlands [19], one in China [14],
and three by an Italian group [7,12,27]. All ﬁve describe an overall re-
duction of risk of 20% as it regards mortality, with a statistical signiﬁ-
cance reached in the Italian and Chinese analyses, but not in the work
by the Dutch group.
In details, the analysis by Landoni et al. [7]was based on 3350 patients
from 27 randomized studies for different indications. Levosimendan was
associated with signiﬁcant reduction in patient mortality, as 17.6% (333/
1893) vs. 22.4% (326/1457) in the levosimendan and control groups, re-
spectively, for an odds ratio of 0.74 (95% conﬁdence interval 0.62–0.89),
at a signiﬁcance of p = 0.001. With levosimendan, myocardial infarction
was seen signiﬁcantly less often, and hypotension signiﬁcantly more
often.
In the more recent analysis by Landoni et al. [12], data from 5480 pa-
tients in 45 studies were included. The overall mortality rate was 17.4%
(507/2915) in levosimendan-treated patients and 23.3% (598/2565) in
the control group, for a risk ratio of 0.80 (95% CI, 0.72–0.89; p b 0.001).
Reduction inmortality was conﬁrmed in studies with placebo or dobuta-
mine as a comparator and in studies performed in cardiac surgery or car-
diology. Length of hospital stay was reduced in the levosimendan group
(weighted mean difference−1.31; 95% CI,−1.95–−0.31; p = 0.007).
The analysis by Huang et al. [14] was performed with randomized
studies to compare the efﬁcacy of levosimendan and dobutamine.
Data from a total of 3052 patients from 22 trials were included. The
use of levosimendanwas associatedwith a signiﬁcant reduction inmor-
tality, as 19.6% (269/1373) vs. 25.7% (328/1, 278), for a risk ratio of 0.81
(95% CI, 0.70–0.92; p= 0.002). The beneﬁt was found in the subgroups
of cardiac surgery, ischemic heart failure, and concomitant β-blocker
therapy.
Koster et al. [19] included data from6688patients in 49 trials in their
analysis. One trial was considered as having ‘low risk’ of bias and nine
trials (representing 2490 patients) as ‘lower risk’ of bias. The pooling
of all trials that included heterogeneous populationswas considered in-
appropriate.When these authors pooled 30 trials that included critically
ill patients who did not have cardiac surgery, a reduction in mortality
was shown (risk ratio, 0.83; 95% CI, 0.59–0.97). However, when only
the trials with lower risk of bias were considered, no signiﬁcant differ-
ence was seen (risk ratio, 0.83; 95% CI, 0.48–1.55). Conversely, their
conventional meta-analysis of the14 trials that included cardiac surgery
patients showed signiﬁcant reduction in mortality with levosimendan
(risk ratio, 0.52; 95% CI, 0.37–0.73), while the same analysis limited to
the studies considered at lower risk of bias did not reach signiﬁcance
(risk ratio, 1.02; 95% CI 0.48–2.16).
Finally, Belletti et al. [27] published an extensive meta-analysis of
177 randomized trials on the effect of inotropes and vasopressors on
mortality. Among the subsetting analysed, the authors pooled 48 stud-
ies on levosimendan and showed a signiﬁcant reduction of mortality
(risk ratio, 0.80; 95% CI 0.68–0.94; p = 0.008).
3.2. Meta-analyses for levosimendan in acute heart failure
Fivemeta-analyses focused on the effects of levosimendan in AHF [4,
5,8,10,24]. One of themwasperformed by a Brazilian research group [8],
one in the United Kingdom [10], and one in China [24]. Finally, twowere
performed over 10 years ago by a group in the United Kingdom and are
Table 1
Meta-analyses of levosimendan clinical studies.
Year References Country/ies Clinical settings No. of studies Main endpoint Relative risk/ odds ratio* Signiﬁcant
2004 Cleland [4] AHF 2a mortality
OR = 0.55
yes
2006 Cleland [5] AHF 4b mortality
OR = 0.75
no
2009 Zangrillo [6] card. surgery 5c troponin release
Z = 3.6
yes
2010 Landoni [7] all 27c mortality
OR = 0.74
yes
Ribeiro [8] AHF 19c mortality
RR = 0.87
no
Landoni [9] card. surgery 10 mortality
OR = 0.35
yes
Delaney [10] AHF 8a mortality
OR = 0.75
yes
2011 Maharaj [11] card. surgery 17c mortality
OR = 0.40
yes
2012 Landoni [12] all 45c mortality
RR = 0.80
yes
Hernandez [13] card. surgery 13c mortality
OR = 0.36
yes
Huang [14] all 22a mortality
RR = 0.81
yes
2013 Harrison [15] card. surgery 14c mortality
RD =−4.2%
yes
Niu [16] AKI/surgery 5c AKI
OR = 0.4
yes
2014 Nieminen [17] rep./AdHF 7c mortality
RR = 0.47
yes
Silvetti [18] rep./AdHF 7c mortality
RR = 0.55
yes
2015 Koster [19] all 49c mortality
RR = 0.69
noe
Bove [20] ARF 33c renal re-placement
RR = 0.52
yes
Greco [21] card. surgery 46d mortality
OR = 0.80
yes
Yi [22] rep./AdHF 8c mortality
RR = 0.40
yes
Lim [23] card. surgery 14c mortality
OR = 0.48
yes
Gong [24] AHF 25c mortality
RR = 0.84
yes
Zangrillo [25] sepsis 7c mortality
RR = 0.79
yes
Silvetti [26] rep./AdHF 7c mortality
RR = 0.54
yes
Belletti [27] all 48c,f mortality
RR = 0.80
yes
Zhou [28] card. surgery 13c AKI and mortality
RR = 0.41g
yes
Only the main analysis of each study is shown for clarity. AHF = acute heart failure; AKI = acute kidney injury; AdHF = advanced heart failure; ARF = acute renal failure;
rep. = repetitive/intermittent use; *if not otherwise speciﬁed (OR = odds ratio; RR = relative risk/risk ratio; RD = risk difference; Z = z-test value); the trend is shown as
an arrow (green = statistically signiﬁcant; yellow = non signiﬁcant).
a compared to dobutamine.
b compared to placebo.
c compared to all controls.
d Bayesian network meta-analysis.
e when only the predeﬁned ‘low bias’ study were considered in the meta-analysis.
f subsetting of randomized studies on levosimendan out of the 177 studies considered in the whole meta-analysis.
g for mortality.
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Fig. 1. Effect of levosimendan on survival. Meta-analysis of the results of the phase II and III clinical trials considered in the regulatory process. These trials included the dose-ﬁnding study
by Slawsky et al. [29], the dose-escalation andwithdrawal study byNieminen et al. [30], the LIDO study by Follath et al. [31], the RUSSLAN study byMoiseyev et al. [32], the SURVIVE study
by Mebazaa et al. [33], and the REVIVE (I and II) study by Packer et al. [34]. #Pooled statistics was calculated using the Cochran–Mante–Haenszel test, controlling for the study.
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reduction of risk as it regards mortality, with a statistical signiﬁcance
reached in the U.K. and Chinese analyses, but not in the work by the
Brazilian group.
In details, Ribeiro et al. [8] included data from 19 studies in their
analysis. In the comparison with placebo (7 trials, 1652 patients), the
RR for overall mortality was 0.87 (95% CI, 0.65–1.18) although this
was not signiﬁcant. In comparisonwith dobutamine (10 trials, 2067 pa-
tients), the relative risk was 0.87 (95% CI, 0.75–1.02), which again was
not signiﬁcant. Three studies reported data on length of hospital stay.
Levosimendan, when compared to placebo and dobutamine, showed
decreases of 2.27 and 2.30 days, respectively (p b 0.05 for both).
Delaney et al. [10] included data from a total of 3650 patients from
19 trials. These authors did not ﬁnd a signiﬁcant reduction in mortality
with levosimendan compared with placebo, odds ratio = 0.83 (95% CI
0.62–1.10; p = 0.20). The result was, however, signiﬁcantly favourable
against dobutamine, odds ratio = 0.75 (95% CI, 0.61–0.92; p = 0.005).
Levosimendanwas associatedwith improvements in hemodynamic pa-
rameters when compared with both placebo and dobutamine.
Gong et al. [24] included data from 5349 patients in 25 trials. In the
total population, levosimendan signiﬁcantly reducedmortality, as 17.1%
vs. 20.8% (risk ratio, 0.84; 95% CI, 0.75–0.94). Compared with dobuta-
mine, levosimendan was also associated with a signiﬁcant reduction
in mortality at the ﬁnal follow up (risk ratio = 0.86; 95% CI, 0.76–
0.97; p = 0.02). Furthermore, compared with placebo, there was a
signiﬁcant reduction in long-term (N6-months) mortality (risk
ratio = 0.34; 95% CI, 0.15–0.76; p = 0.009). Levosimendan was
also associated with signiﬁcant improvements in hemodynamic
and echocardiographic-derived parameters, although it increased the
risks of extrasystoles, hypotension, and headache or migraine. One ad-
vantage with this meta-analysis is that the effects of levosimendan on
short-, mid- and long-termmortality are presented separately. However,
these ﬁndings by Gong et al. [24] have to be interpreted with some cau-
tion, as it appears that they included the SURVIVE study data [33] twice
in the analysis.
For the sake of completeness we cite two early meta-analyses by
Cleland et al. [4,5], in which the few trials completed at that time werepooled (2004, 2006, respectively). These papers describe early meta-
analyses on levosimendan, although their results are no longer directly
relevant as they have been superseded by further meta-analyses.3.3. Meta-analyses for intermittent use of levosimendan in advanced
chronic heart failure
Four meta-analyses focused on the effects of repetitive infusions of
levosimendan in advanced chronic heart failure [17,18,22,26]. One
was performed by an Italian group [18], one by a European panel of ex-
perts [17], and one by a Chinese group [22]. Finally, one was a coopera-
tion between an Italian and a Finnish group [26]. All four describe a
statistically signiﬁcant overall reduction of risk as it regards mortality.
In details, the meta-analyses produced by Nieminen et al. [17],
Silvetti et al. [18], and Silvetti and Nieminen [26] are considering the
studies in which the effects of intermittent or repetitive levosimendan
treatment on AdHF patients were described. Of the 10 studies found
in the literature, Nieminen et al. [17], and Silvetti et al. [18] selected
groups of 7 studies each, which were not fully overlapping.
Nieminen et al. [17] considered a total of 345 patients and showed
that levosimendan was associated with a signiﬁcant reduction in
mortality (risk ratio, 0.47; 95% CI, 0.32–0.70; p = 0.0002). Silvetti et al.
[18] also showed that levosimendan was associated with a signiﬁcant
reduction in mortality, here at the longest follow-up available, as 19%
(32/168) vs. 35% (46/133) in the control arm, with relative risk = 0.55
(95% CI 0.37–0.84; p = 0.005). Both of these meta-analyses were, how-
ever, criticized for their selection of studies [36].
When new studies became available a corrected and updated meta-
analysis was produced [18] in which a total of 438 adult patients on
intermittent levosimendan treatment in a cardiological setting
were included, with an average follow-up period of 8 ± 3.8 months.
The use of levosimendan was associated with a signiﬁcant reduction
in mortality at the longest follow-up available, as 16% (41/257) in the
levosimendan group vs. 21.5% (39/181) in the control group (OR,
0.54; 95% CI, 0.32–0.91; p for effect, 0.02; p for heterogeneity, 0.64;
I2, 0%).
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peated levosimendan infusions. Here, levosimendan signiﬁcantly re-
duced mortality, as 10.2% (23/226) vs. 26.8% (53/198) in the control
arm (relative risk, 0.40; 95% CI 0.26–0.63; p b 0.0001).3.4. Meta-analyses for levosimendan in surgery
Ten meta-analyses focus on the effects on the peri-operative uses of
levosimendan in cardiac surgery [6,9,11,13,15,16,20,21,23,28]. Four
were performed by an Italian group [6,9,20,21], one by a group in
the U.K. [11], one in the U.S.A. [15], one in Spain [13], two in China
[16,28], and one was published as a cooperation of various interna-
tional research groups [23]. The eight meta-analyses describing an
effect on mortality [6,9,11,13,15,21,23,28] concur in a statistically
signiﬁcant overall reduction of risk. Also the two which describe renal
effects [16,20] concur in a statistically signiﬁcant overall reduction of
risk.
In details, Zangrillo et al. [6] performed the ﬁrst meta-analysis in the
cardiac surgery ﬁeld on a total of 139 patients from ﬁve studies. The end-
point was postoperative peak cardiac troponin release. Levosimendan
was found to have signiﬁcantly lower peak release than the comparators,
with a weighted mean difference of 2.5 ng/dL (range, 1.14–3.86; p =
0.0003).
When Landoni et al. [9] updated themeta-analysis by Zangrillo et al.
[6], 440 patients from 10 studies were included. Levosimendan was
associated with a signiﬁcant reduction in postoperative mortality, as
4.7% (11/235) in the levosimendan group versus 12.7% (26/205) in the
control arm (OR, 0.35; 95% CI, 0.18–0.71; p = 0.003).
In their meta-analysis, Maharay et al. [11] included 729 patients
from 17 studies. Levosimendanwas associatedwithmortality reduction
after coronary revascularization, as 4.9% (19/386) versus 11.4% (39/
343) in the control arm (OR, 0.40; 95% CI, 0.21–0.76; p = 0.005).
Levosimendan also signiﬁcantly improved cardiac index, shortened in-
tensive care unit stay, and reduced rate of atrial ﬁbrillation and magni-
tude of postoperative troponin I release.
Hernandez et al. [13] included 654 patients from 13 studies in their
analysis (published in Spanish). Levosimendan was associated with a
signiﬁcant reduction in postoperative mortality, as 5.2% (18/344)
versus 12.6% (39/310) in the control arm (OR, 0.36; 95% CI, 0.20–0.64;
p = 0.001).
Harrison et al. [15] included 1155 patients from 14 studies in their
analysis. Here, patients with a mean left ventricular ejection fraction
(LVEF) b40% were deﬁned as low-EF. The pooled data demonstrated
reduction in mortality with levosimendan, as risk difference (RD)
−4.2% (95% CI, −7.2%, −1.1%; p = 0.008). Subgroup analysis
showed that this beneﬁt was conﬁned to the low-EF studies, as RD
−7.0% (95% CI,−11.0%,−3.1%; p b 0.001). No beneﬁt was observed
in the preserved-EF subgroup. Signiﬁcant reductions were also seen in
the need for dialysis, as RD−4.9% (95% CI,−8.2%,−1.6%; p = 0.003),
for postoperative atrial ﬁbrillation, as RD −8.1% (95% CI, −13.3%,
−3.0%; p = 0.002) and for myocardial injury, as RD −5.0% (95% CI,
−8.3%,−1.7%; p = 0.003).
Niu et al. [16] included data from 529 patients in ﬁve trials to demon-
strate that levosimendan is associated with a lower incidence of acute
kidney injury (AKI). Indeed, only 9.5% (25/264) in the levosimendan
group, compared to 19.2% (51/265) in the control group, developed
AKI (OR, 0.44; 95% CI, 0.22–0.85; p = 0.02).
Similarly, Bove et al. [20] included 3879 patients from 33 trials in a
meta-analysis evaluating the effect of levosimendan on the need of
renal replacement therapy. The incidence of renal replacement therapy
was 3.5% (17/492) in the levosimendan group versus 8.7% (37/427) in
the control group (RR, 0.52; 95% CI, 0.32–0.86; p = 0.01). AKI (as per
author's deﬁnition) was also examined, where levosimendanwas asso-
ciated with lower incidence of 7.1% (114/1598) versus 9.4% (143/1529)
in the control group (RR, 0.79; 95% CI, 0.63–0.99; p = 0.048).The objective of the study by Greco et al. [21] was to conduct a
Bayesian network meta-analysis on the effects of inodilators on sur-
vival in adult cardiac surgery patients, and to compare and rank
these drugs, as they had not been adequately compared in head-
to-head trials. The following drugs were evaluated: dobutamine,
enoximone, levosimendan, and milrinone. The data were based on
2647 patients in 46 trials. Only the use of levosimendan was associated
with decrease in mortality when compared with placebo (posterior
mean of OR, 0.48; 95% CI, 0.28–0.80). The posterior distribution of the
probability for each inodilator to be the best and theworst drug showed
that levosimendan was the best agent for the improvement of patient
survival after cardiac surgery (90.8%, as posterior distribution derived
by Bayesian hierarchical model with Markov Chain Monte Carlo
algorithm).
Lim et al. [23] considered a total of 965 patients in 14 studies. Here,
levosimendan signiﬁcantly reduced early patient mortality, although as
for the Harrison analysis [15], the favourable data were driven by the
studies with low preoperative EF, as 4.2% (15/360) versus 9.5% (34/
357) (OR, 0.41; 95% CI, 0.24–0.77; p = 0.004). In the levosimendan
group, postoperative acute renal failure was less frequent, and inten-
sive care unit stay was shorter.
Finally, Zhou et al. [28] published a meta-analysis of 13 trials with a
total of 1345 study patients, in which levosimendan was compared to
control of the incidence of postoperative AKI, renal replacement thera-
py, duration of mechanical ventilation, intensive care unit stay, and
post-operative mortality. Levosimendan was statistically superior in
all parameters. As it regards mortality, OR was as low as 0.41 (95% CI,
0.27–0.62; p b 0.002). Postoperative AKIU was also reduced, with
OR = 0.51 (95% CI, 0.34–0.76; p = 0.001).
3.5. Meta-analyses for levosimendan in sepsis
In the meta-analysis by Zangrillo et al. [25], 246 patients were in-
cluded from seven studies. Levosimendan was associated with signiﬁ-
cantly reduced patient mortality compared with standard inotropic
therapy, as 47% (59/125) versus 61% (74/121) (risk ratio, 0.79; 95% CI,
0.63–0.98; p= 0.03). In the levosimendan group, blood lactate was sig-
niﬁcantly lower and cardiac index was signiﬁcantly higher. No differ-
ences inmean arterial pressure and norepinephrine usewere observed.
3.6. Other pooled analyses and meta-analyses
For the sake of completeness, we also cite here the study of Kivikko
et al. [37], which is a pooled analysis (i.e., not ameta-analysis) of six ran-
domized levosimendan trials, with a total of 3004 patients, of which
1700were treatedwith levosimendan and 226with both levosimendan
and sulfonylureas. Here, the authors concluded that concomitant use of
sulfonylureas and levosimendan does not attenuate the hemodynamic
or other effects of levosimendan. Among the data, there was a nonsig-
niﬁcant reduction in mortality in the levosimendan arms (with and
without concomitant sulfonylureas), as 9.9% (169/1700) versus 11.3%
(147/1304) for the comparators.
Again for the sake of completeness we cite also a meta-analysis by
Qiao et al. [38], published very recently, in which levosimendan was
found to be associated with a reduction in postoperative mortality of
high-risk surgical patients with multi organ dysfunction syndrome
(4.7% in the levosimendan group vs. 12.7% in the control; odds ratio of
0.35 [0.18–0.71], p for effect 0.003; 440 patients included).
4. Discussion
The general trend of themeta-analyses we have evaluated here was
to include only published data from randomized double-blind studies.
In some cases, data published as abstracts were considered. All meta-
analyses that we scrutinized here duly evaluated the internal validity
and risk of bias of the trials that they included, according to the
82 P. Pollesello et al. / International Journal of Cardiology 209 (2016) 77–83Cochrane Collaboration methods [39], with divergences resolved by
consensus between the authors responsible for the selection. Publica-
tion bias is commonly assessed by visually inspecting funnel plots, or
by analytical appraisal based on the Begg adjusted-rank correlation
test [40] andEgger's linear regression test [41]. In several cases, sensitiv-
ity analyses were performed by sequentially removing each study and
re-analysing the remaining dataset (producing a new analysis for each
study removed), and by analysis of data from studies with moderate
and low risk of bias. Some exceptions were justiﬁed on a case-to-case
basis.
Koster et al. [19] criticized the other meta-analyses because the bias
levels of the studies are generally acknowledged a posteriori but not
used a priori as a parameter for the selection of the publications to be
included.
It can be noted that nearly all of the meta-analyses included sub-
analyses of smaller sets of studies to address speciﬁc questions, in
terms of settings, comparators, end-points, adverse events, and others.
As an example, the meta-analysis of Landoni et al. [12] considered 45
clinical trials, but included also sub-analyses for the cardiology and
cardiac surgery settings, for dobutamine or placebo as comparators,
and for use of a bolus dose of levosimendan or not. In terms of the com-
parators, many meta-analyses considered these separately, in terms of
the studies in which levosimendan was compared to an active drug
(e.g. dobutamine, milrinone, enoximone), and the studies where the
comparator was a placebo. In this regard, it must also be noted that
due to the severity of the patient status, in the majority of cases active
treatment and placebo were given on top of the best standard of care,
or ‘rescue’ inotropic therapy was allowed (mainly inotropes or vaso-
pressors). Thus the deﬁnition of ‘placebo’ as the control can vary from
study to study, and from meta-analysis to meta-analysis.
Our meta-analysis on the effect of levosimendan on patient mortal-
ity incorporated only the six phase II and III randomized double-blind
trials which were included in the regulatory registration proceedings
for levosimendan. It is worth noting that the RR obtained was very sim-
ilar to those provided by all of the other meta-analyses considered in
this review, albeit for only borderline signiﬁcance.
As it regards meta-analyses focused on the use of levosimendan in
peri-operative settings, it has to be mentioned that there may be sub-
stantial differences in the pathophysiology of myocardial dysfunction
(e.g. LV vs. RV, or ischemia vs. load) in different types of surgical proce-
dure (e.g. all cardiac surgeries, just valve procedures, and just CABG).
Many of themeta-analyses described in this text do consider separately
the studies on low EF patients from the high EF ones (e.g. the meta-
analysis by Harrison et al. [15]).
At themoment, several studies on levosimendan are still ongoing. In
the cardiosurgical ﬁeld, data from the LICORN, LEVO-CTS and LEVO-HSR
studies (for a total of N1500 patients) are expected in 2016–17 [42]. In
the cardiac ﬁeld, data from the LION-HEART, LAICA, and ELEVATE
studies (for a total of N250 patients) are also expected in 2016 [17]. In
addition, the LeoPARDS study (516 patients) will shed some light on
the effects of levosimendan in sepsis [43]. All in all, several studies
that include a total of over 2250 patients are ongoing, and thus new or
updated meta-analyses will probably be performed which could
strengthen the evidence of survival beneﬁts by levosimendan.
5. Conclusions
We have reviewed 25meta-analyses on levosimendan, by 16 differ-
ent research groups, and found that these have consistently showed
beneﬁts for levosimendan, with lower relative risk (or odds ratio) in
the key endpoint of patient mortality. In 3/25 of these meta-analyses
these beneﬁcial signs did not reach statistical signiﬁcance, while in 22/
25, signiﬁcance was demonstrated. The RR overall is relatively consis-
tent, and very similar to that obtained in our meta-analysis that consid-
ered only the regulatory studies. All in all, the existing meta-analyses
have been based on a population of over 6000 patients, and the generaltrend is towards signiﬁcant beneﬁts. It thus appears that the weight of
evidence is in favour of the usefulness/efﬁcacy of levosimendan, with
data from multiple randomized trials and meta-analyses.
Levosimendan can thus be differentiated from other hemodynami-
cally active drugs used in the same settings [44]. An overall worse prog-
nosis in themid-term to long-term has indeed been associatedwith the
use of dobutamine and PDE inhibitors in two focused meta-analyses by
Tacon et al. [45] and Nony et al. [46], respectively. These authors
concluded that dobutamine and PDE inhibitors do not provide any ben-
eﬁts in terms of patient survival. It appears thus wrong to consider
‘inotropes’ or ‘inodilators’ as a unique family of drugswith the same pat-
tern of efﬁcacy and safety.Author contributions
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